Oncology
Advanced Urothelial Cancer
0
Pipeline Programs↗
5
Active Trials↗
6
Companies Involved↗
Advanced Urothelial Cancer is an early-stage landscape with 0 programs across 6 companies. The most active players are Merck & Co., Generate Biomedicines, WiSP Wissenschaftlicher Service Pharma GmbH.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
25
clinical trials
Completed14 · 56%
Terminated3 · 12%
Recruiting3 · 12%
Withdrawn3 · 12%
Not yet recruiting1 · 4%
Active, not recruiting1 · 4%
Clinical Trials
Trial Activity
25 trials
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT06820255·135 enrolled
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Completed·—·Phase 2·NCT01426126·37 enrolled
Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study
Completed·—·Phase 2·NCT03891238·67 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)